Damian Mojsak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Damian Mojsak has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Kasiukiewicz
Department of Geriatrics, Medical University of Bialystok, 15-471 Bialystok, Poland
1 shared publication - Anna Moniuszko-Malinowska
Department of Infectious Diseases and Neuroinfection, Medical University of Bialystok, Żurawia 14, 15-540 Bialystok, Poland
1 shared publication Beata Kuklińska
2nd Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland
1 shared publication- Beata Kuklińska
2nd Department of Lung Diseases and Tuberculosis, Medical University of Białystok,14 Żurawia Street, 15-540 Bialystok, Poland
1 shared publication - Federico Zara
Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
1 shared publication - Floriana Guida
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, 16132 Genoa, Italy
1 shared publication
Latest Publications
- Open Access
- 27 September 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (10) , 1455
ATP12A Proton Pump as an Emerging Therapeutic Target in Cystic Fibrosis and Other Respiratory Diseases
ATP12A encodes the catalytic subunit of the non-gastric proton pump, which is expressed in many epithelial tissues and mediates the secretion of protons in exchange for potassium ions. In the airways, ATP12A-dependent proton secretion contributes to complex mechanisms regulating the composition and properties of the fluid and mucus lining the respiratory epithelia, which are essential to maintain the airway host defense and the respiratory health. Increased expression and activity of ATP12A in combination with the loss of other balancing activities, such as the bicarbonate secretion mediated by CFTR, leads to excessive acidification of the airway surface liquid and mucus dysfunction, processes that play relevant roles in the pathogenesis of cystic fibrosis and other chronic inflammatory respiratory disorders. In this review, we summarize the findings dealing with ATP12A expression, function, and modulation in the airways, which led to the consideration of ATP12A as a potential therapeutic target for the treatment of cystic fibrosis and other airway diseases; we also highlight the current advances and gaps regarding the development of therapeutic strategies aimed at ATP12A inhibition.
- 27 September 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (10) , 1455
Open AccessATP12A Proton Pump as an Emerging Therapeutic Target in Cystic Fibrosis and Other Respiratory Diseases
ATP12A encodes the catalytic subunit of the non-gastric proton pump, which is expressed in many epithelial tissues and mediates the secretion of protons in exchange for potassium ions. In the airways, ATP12A-dependent proton secretion contributes to complex mechanisms regulating the composition and properties of the fluid and mucus lining the respiratory epithelia, which are essential to maintain the airway host defense and the respiratory health. Increased expression and activity of ATP12A in combination with the loss of other balancing activities, such as the bicarbonate secretion mediated by CFTR, leads to excessive acidification of the airway surface liquid and mucus dysfunction, processes that play relevant roles in the pathogenesis of cystic fibrosis and other chronic inflammatory respiratory disorders. In this review, we summarize the findings dealing with ATP12A expression, function, and modulation in the airways, which led to the consideration of ATP12A as a potential therapeutic target for the treatment of cystic fibrosis and other airway diseases; we also highlight the current advances and gaps regarding the development of therapeutic strategies aimed at ATP12A inhibition.
- Open Access
- 15 January 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (2) , 1583
Impact of COVID-19 in Patients with Lung Cancer: A Descriptive Analysis
The COVID-19 pandemic poses a challenge to health systems worldwide. Limiting healthcare availability may delay early diagnosis and worsen the treatment effects of various diseases, including oncological diseases. We analyzed patients presenting to the 2nd Department of Lung Diseases and Tuberculosis in Białystok, Poland, with suspicion of lung cancer 12 months prior to the COVID-19 pandemic (pre-COVID-19) and, similarly, 12 months after the outbreak of the pandemic (mid-COVID). In total, 320 patients were analyzed—132 prior to and 188 after the COVID-19 outbreak. During the COVID-19 period, there was a lower percentage of patients presenting with ECOG performance status 0-1, with a noticeably increased percentage of patients with ECOG PS ≥2. The disease’s clinical stage (CS) was higher on admission during COVID-19. We observed more use of immunotherapy and more deaths before the start of treatment during the COVID-19 period. These results provide insight into the early effects of the COVID-19 pandemic on lung cancer patients and underscore the importance of conducting further studies to assess the long-term effects of the COVID-19 pandemic on this population.
- 15 January 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (2) , 1583
Open AccessImpact of COVID-19 in Patients with Lung Cancer: A Descriptive Analysis
The COVID-19 pandemic poses a challenge to health systems worldwide. Limiting healthcare availability may delay early diagnosis and worsen the treatment effects of various diseases, including oncological diseases. We analyzed patients presenting to the 2nd Department of Lung Diseases and Tuberculosis in Białystok, Poland, with suspicion of lung cancer 12 months prior to the COVID-19 pandemic (pre-COVID-19) and, similarly, 12 months after the outbreak of the pandemic (mid-COVID). In total, 320 patients were analyzed—132 prior to and 188 after the COVID-19 outbreak. During the COVID-19 period, there was a lower percentage of patients presenting with ECOG performance status 0-1, with a noticeably increased percentage of patients with ECOG PS ≥2. The disease’s clinical stage (CS) was higher on admission during COVID-19. We observed more use of immunotherapy and more deaths before the start of treatment during the COVID-19 period. These results provide insight into the early effects of the COVID-19 pandemic on lung cancer patients and underscore the importance of conducting further studies to assess the long-term effects of the COVID-19 pandemic on this population.
- Open Access
- 1 September 2021
- Published by Elsevier in Advances in Medical Sciences
- Vol. 66 (2) , 381-387
Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review
- 1 September 2021
- Published by Elsevier in Advances in Medical Sciences
- Vol. 66 (2) , 381-387
Open AccessCurrent state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review